Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 19 (2004), Issue 6, Pages 259-261
http://dx.doi.org/10.1155/2004/826408

GSTT1 Gene Deletion Is Associated with Lung Cancer in Mexican Patients

M. P. Gallegos-Arreola,1 B. C. Gómez-Meda,1 G. Morgan-Villela,2 M. R. Arechavaleta-Granell,3 L. Arnaud-López,1 T. J. Beltrán-Jaramillo,4 R. Gaxiola,5 and G. Zúñiga-González1

1División de Medicina Molecular, Centro de Investigación Biomédica de Occidente, Guadalajara Jalisco, México
2Servicio de Oncología, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara Jalisco, México
3Servicio de Endocrinología, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara Jalisco, México
4Servicio de Urgencias, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara Jalisco, México
5Servicio de Epidemiología, Guadalajara Jalisco, México, Hospital de Especialidades, Centro Médico Nacional de Occidente, IMSS, Guadalajara Jalisco, México

Received 13 July 2004; Accepted 13 July 2004

Copyright © 2004 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Glutathione S-transferase (GST) is a dimeric detoxifying isoenzyme, involved in the deactivation of carcinogens, several tobacco-derived carcinogens, and xenobiotics. It catalyzes the reduction of glutathione to its thioester; thus, deficiency in GST activity due to homozygous deletion of the GSTT1 gene (null genotype) may play a role in the induction of lung cancer by smoking.

We studied the distribution of GSTT1 gene deletion in peripheral blood DNA samples from 178 healthy controls (41 nonsmokers, 63 passive smokers and 74 smokers) and 52 lung cancer patients. Comparisons between groups showed that there was an increased lung cancer risk for individuals with the GSTT1 null genotype. Cancer patients showed significant differences when compared with controls: nonsmokers, passive smokers, and smokers. Twenty-one percent of lung cancer patients carried the deletion versus 2% among nonsmokers not exposed to passive smoking, 6% among passive smokers, and 5% among smokers. Thus, there is a significant association between this genotype and the possibility to risk of developing lung cancer.